Today: 19 November 2025
Subscribe
Browse Category

Eli Lilly News 16 September 2025 - 2 November 2025

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

Market Snapshot (pre-market Nov 3) As of Oct. 31 close, Eli Lilly (NYSE:LLY) was around $862–864 (with after-hours ~864) stockanalysis.com marketbeat.com. That’s up ~9–10% from early October nasdaq.com. Trading volumes have been heavy, and LLY remains near its 52-week high (~$935) marketbeat.com. MarketBeat notes LLY’s 50-day moving average is ~$780 marketbeat.com, reflecting the recent surge. Institutional ownership is high (~82.5% by funds marketbeat.com) and sentiment is bullish. Blowout Q3 & Raised Guidance Lilly’s Q3 (announced Oct 30) blew past forecasts. Revenue was $17.60 billion (+54% YoY) with EPS $7.02 marketbeat.com, versus consensus ~$16.1 B/$5.9. Key GLP-1 drugs led the surge. The company
2 November 2025
 ·  ·  ·  ·  · 
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock Surges on Obesity-Drug Boom – Is $1,000 Next?

Stock Market Performance In early October 2025, Eli Lilly (NYSE: LLY) stock leapt upward. After closing around $726 on Sept. 29 and ~$763 on Sept. 30 nasdaq.com, it spiked to about $832 intraday on Oct. 1. Trading volumes were well above average on that run. Financial media noted a flurry of bullish option trades and news-driven optimism: a major study found that GLP-1 weight-loss drugs (like Lilly’s Mounjaro) may significantly reduce Alzheimer’s risk fiercepharma.com, feeding excitement about Lilly’s broad pipeline. Tip-rank and investing sites attributed the rally to strong earnings, insider buying, and renewed interest in Lilly’s obesity/Alzheimer’s franchise tipranks.com fiercepharma.com. Overall, LLY’s
1 October 2025
 ·  ·  ·  ·  · 
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly’s Weight-Loss Pill Sheds Pounds Fast—But Hits a Plateau: What New Trial Results Mean for the Obesity Drug Race

Trial Results: Big Early Losses, Then Weight Loss Levels Off This highly anticipated trial put Lilly’s oral GLP-1 drug, orforglipron, to the test in a large group of adults struggling with obesity. The study enrolled 3,127 overweight or obese participants (none had diabetes, but all had weight-related health issues) and randomly assigned them to various daily doses of the pill or a placebo for 72 weeks reuters.com. The outcomes were encouraging yet mixed. Patients on the highest dose (36 mg daily) lost on average about 11–12% of their starting body weight by week 72 theguardian.com. In practical terms, that’s roughly
17 September 2025
 ·  ·  ·  ·  ·  · 
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Richmond’s New Pharma Giant: Overview of Lilly’s $5B Factory Eli Lilly’s forthcoming Richmond-area factory is set to be one of the largest and most advanced pharmaceutical manufacturing sites in the world. At a cost of $5 billion, Lilly will construct a high-tech production campus in Goochland County’s West Creek Business Park, a site that had been prepped for a previous project and now deemed “the perfect spot” for fast construction washingtonpost.com. The facility’s core mission: make more of the critical drug ingredients that Lilly usually sources overseas, right here on U.S. soil washingtonpost.com washingtonpost.com. Scale and Scope: The plant will
16 September 2025
 ·  ·  ·  ·  ·  ·  ·  ·  · 
Go toTop